.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The MAESTRO-NASH phase 3 trial evaluated resmetirom in adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with significant liver fibrosis. At 52 weeks, resmetirom produced higher rates of both MASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of MASH compared with placebo. The trial is important because it demonstrates a path toward disease-modifying pharmacotherapy in a condition historically managed largely through lifestyle intervention and treatment of metabolic risk factors. For internists, MASLD/MASH is increasingly relevant because obesity, type 2 diabetes and cardiovascular disease frequently coexist with liver disease. Risk assessment should therefore move beyond liver enzymes alone and incorporate fibrosis estimation and appropriate referral pathways. Resmetirom is not appropriate for every patient with fatty liver, and the trial population had selected fibrosis stages. Nonetheless, the results reinforce the idea that MASH can be an active therapeutic target rather than simply an incidental imaging finding. Multidisciplinary management remains essential, with attention to weight, glycemia, lipids, blood pressure, alcohol exposure and cardiovascular risk.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The MAESTRO-NASH phase 3 trial evaluated resmetirom in adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with significant liver fibrosis. At 52 weeks, resmetirom produced higher rates of both MASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of MASH compared with placebo. The trial is important because it demonstrates a path toward disease-modifying pharmacotherapy in a condition historically managed largely through lifestyle intervention and treatment of metabolic risk factors. For internists, MASLD/MASH is increasingly relevant because obesity, type 2 diabetes and cardiovascular disease frequently coexist with liver disease. Risk assessment should therefore move beyond liver enzymes alone and incorporate fibrosis estimation and appropriate referral pathways. Resmetirom is not appropriate for every patient with fatty liver, and the trial population had selected fibrosis stages. Nonetheless, the results reinforce the idea that MASH can be an active therapeutic target rather than simply an incidental imaging finding. Multidisciplinary management remains essential, with attention to weight, glycemia, lipids, blood pressure, alcohol exposure and cardiovascular risk.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
